INOVIQ (ASX:IIQ) has completed a proof-of-concept (POC) study showing that exosomes—tiny vesicles released from cells—can be ...

In a Type B meeting, the FDA signified that it will allow uniQure to use a natural history control, the composite Unified ...

The oligonucleotides market has gained significant traction in recent years due to its critical role in molecular biology, genetics, and therapeutics. Oligonucleotides, short DNA or RNA molecules, are ...

New therapies that are less intrusive but more lasting than current interventions promise to arrest and even reverse neurodegeneration.

Monte Rosa Therapeutics stock surged after a recent partnership with Novartis, despite limited clinical results. Can the ...

NDAQ:STOK) Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome ...

In Series I, we shared Mila's compelling story and the development history of milasen, while also exploring the FDA guidance ...

Behavioral activation therapy helps individuals break the cycle of inactivity and low mood by encouraging engagement in meaningful activities, even when motivation is low. If you’re looking for ...

The antisense oligonucleotide company also received a big cash injection in March 2024 after a $100 million private placement. Sarepta Therapeutics has a pipeline of programs in various stages of ...

All antisense oligonucleotides were designed according to the genetic sequence of the DENV-2 (NCBI GenBank, NC_001474.2), and all antisense oligonucleotides were provided by 4A Biotech Co., Ltd.

The study showed that when the researchers injected a compound called BCC10 linked to specialized genetic tools known as antisense oligonucleotides into mice, it successfully reduced the activity ...